Drug cost-effectiveness organisation ICER has revised its view of Eisai’s new Alzheimer’s disease therapy Leqembi, but has concluded that the price set by the pharma group is still too high.
It seems Eisai and Biogen have another hurdle to jump over in their bid to get EU approval for their Alzheimer's disease therapy Leqembi. In the latest development, the European Commission has ...
Elon Musk highlighted “entitlements spending”—which includes Social Security and Medicare—as one of his prime targets for massive cuts in an interview with Fox Business Network on Monday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback